Genovis introduces a new service concept
Genovis is launching a service through which customers can order antibody fragmentation with “Smart Enzymes,” thereby opens a new market niche for the company's products.
Genovis’ products are marketed under the name “Smart Enzymes” and are used to process antibodies and split them into smaller fragments. To date, the products have been marketed primarily for characterization of biologics. Customers use small quantities of the products in a large number of samples to divide the drug candidate into smaller fragments, which are then analyzed. All of the products are also highly effective with production of larger amounts of antibody fragments, which are required in several different studies in preclinical drug discovery. Genovis is now also focusing on this market and is launching a service through which customers order antibody fragmentation.
Implementation of new technology often requires resources. Buying the products that are necessary to fragment large quantities of antibodies represents an investment for the customer. By offering this service, Genovis can provide customers with quick results and facilitate technology transfer to the customer, thereby minimizing the customer’s technology-associated risk and costs for the actual project. Subsequently, the customer can choose to continue to have Genovis do the work, or buy the required products and carry out the project in-house. Genovis has met a need and has worked closely with customers on projects in the past. Now the company will take the concept to the next stage and actively offer the service as part of its range of services to existing and new customers.
“Our knowledge about our enzymes and the fact that we can process and analyze them on a routine basis allows us to provide high-quality quick results. We have extensive cumulative expertise in-house, and that knowledge is extremely valuable for customers who are new to both the products and the technology. Our service generates revenue by quickly bridging the technology transfer gap to customers and in the long term will open up a new market niche for our products. The combination with our endotoxin-free products allows us to focus on a broad target group for both in vitro and in vivo tests in studies such as target validation in the pharmaceutical industry. Offering a service is completely in line with our strategy for developing new markets in collaboration with our customers,” says Sarah Fredriksson, CEO of Genovis
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 email@example.com
Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.
Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is Certified Adviser for the Company, t: 46 (0)31-745 50 00